Eli Lilly announces positive results from Phase 2 trial of eloralintide

Eli Lilly (LLY) “announced positive results from a Phase 2 trial evaluating the safety and efficacy of eloralintide, an investigational once-weekly, selective amylin receptor agonist, in 263 adults with obesity or overweight with at least one obesity-related comorbidity and without type 2 diabetes. At 48 weeks, all treatment arms of eloralintide met the primary endpoint, demonstrating superior mean weight reductions from 9.5% to 20.1% compared to 0.4% with placebo using the efficacy estimand.1 Results from the trial were presented at ObesityWeek 2025 and simultaneously published in The Lancet. In the trial, all doses of eloralintide delivered clinically meaningful improvements compared to placebo for the secondary endpoints of reductions in body weight and body mass index. Treatment with eloralintide was also associated with improvements across cardiometabolic risk factors including waist circumference, blood pressure, lipid profiles, glycemic control and markers of inflammation.”